Pipeline

Ganetespib

Hsp90 Inhibitor

Ganetespib, an investigational drug, is a small molecule inhibitor of heat shock protein 90 (Hsp90), a molecular chaperone required for the proper maturation and activation of numerous client proteins. Many of these Hsp90 client proteins play critical roles in cell growth, differentiation, and survival. Relative to normal cells, cancer cells are more reliant on elevated levels of the active form of Hsp90 and, as such, appear to be selectively sensitive to Hsp90 inhibitors, including ganetespib. Currently, there are two active and ongoing investigator sponsored trials on ovarian cancer (GANNET53) and sarcoma (SARC 023).